Wall Street closes at a record for the first time since end of January
ATLANTA - Emory Healthcare has completed robotic peripheral endovascular procedures using Microbot Medical’s (NASDAQ:MBOT) LIBERTY Endovascular Robotic System, according to a press release statement. The medical robotics company’s shares have surged 66% over the past year, trading at $2.53 with a market capitalization of $170 million, though analysts maintain price targets ranging from $5 to $12.
The procedures included what the company describes as the first robotic prostate artery embolization for benign prostatic hyperplasia and robotic Y-90 radioembolization mapping for liver cancer.
Prostate artery embolization is a minimally invasive, image-guided outpatient procedure that works to shrink the prostate by blocking its blood supply. Published research indicates that BPH affects approximately 40 million men in the U.S.
"Using the new system for PAE assists in navigating and handling challenging anatomy with precision," said Zachary L. Bercu, an interventional radiologist with Emory Healthcare and professor at Emory University School of Medicine.
The Y-90 radioembolization mapping procedure allows specialists to visualize blood vessels in advance of treatment. The procedure involves injecting tiny beads containing the radioactive isotope yttrium-90 inside blood vessels that feed a tumor.
The LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. The system is designed for vascular navigation while aiming to reduce radiation exposure and physical strain.
Microbot Medical commenced the Limited Market Release of the LIBERTY system in November 2025 and plans for a Full Market Release at the Society of Interventional Radiology conference in April 2026. According to InvestingPro analysis, the stock currently trades above its Fair Value, placing it on the platform’s Most Overvalued list despite strong momentum this year.
Emory Healthcare operates 11 hospitals with 3,028 licensed patient beds and more than 3,800 physicians practicing in over 70 specialties, serving metro Atlanta and Georgia.
In other recent news, Microbot Medical Inc. announced that a study evaluating its LIBERTY Endovascular Robotic System has been published in the Journal of Vascular and Interventional Radiology. The study, led by Dr. Francois Cornelis, highlights the feasibility of this robotic system for arterial peripheral vascular interventions. Additionally, the company emphasized that its LIBERTY system addresses radiation exposure concerns, aligning with the American Medical Association’s new protective policies adopted in late 2025. These policies focus on reducing occupational radiation exposure for healthcare professionals.
Microbot Medical also reported that its operations in the United States and Israel remain unaffected by geopolitical events in the Middle East, ensuring continued manufacturing and commercial activities. In other developments, H.C. Wainwright reiterated a Buy rating for Microbot Medical, with a price target of $12.00, following the adoption of the LIBERTY system by Tampa General Hospital in Florida. The hospital’s Division Chief of Vascular Surgery noted the system’s benefits in enhancing patient care and reducing radiation risks for physicians.
Furthermore, Microbot Medical disclosed changes to its executive compensation structure, including an increased base salary and bonus potential for its Chief Technology Officer, Simon Sharon. The company also authorized a special bonus for its CEO, as outlined in a recent SEC filing. These adjustments reflect performance metrics and criteria set by the Compensation Committee or the Board of Directors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.